- Immatics N.V. (NASDAQ:IMTX) announced a clinical data update for the IMA203 monotherapy from the Phase 1a dose escalation part of the trial and initial data from the ongoing Phase 1b dose expansion cohort A (monotherapy).
- In the Phase 1 trial, IMA203 continues to be well tolerated and achieved confirmed objective responses across multiple solid cancers.
- A positively evolving durability profile for IMA203 was observed at higher doses.
- 6 of 12 patients (50%) treated with more than 1 billion infused TCR-T cells (DL4 and DL5) in the Phase 1a and Phase 1b cohort A part of the trial experienced a confirmed objective response.
- In the Phase 1b part of the trial alone, 4 of 5 patients (80%) had a confirmed objective response which was all ongoing at the timepoint of data cut-off.
- No additional dose-limiting toxicities (DLT) have been observed since the initial data release in March 2021.
- Further data read-outs on the individual cohorts are planned throughout 2023.
- Immatics also announced underwritten public offering of 10.9 million shares at $10.09 per share for gross proceeds of approximately $110 million.
- Price Action: IMTX shares are up 16.10% at $11.72 during the premarket session on the last check Monday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
